Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Bram D. Zuckerman"'
Autor:
Martin B. Leon, Pamela Goldberg, Jon Hunt, Bram D. Zuckerman, Aaron V. Kaplan, David R. Holmes, Robert 'Chip' Hance, Michael J. Mack, Jaime Walkowiak, Andrew Farb, Liliana Rincon-Gonzalez
Publikováno v:
Journal of the American College of Cardiology. 76:2786-2794
The development of technology to treat unmet clinical patient needs in the United States has been an important focus for the U.S. Food and Drug Administration and the 2016 Congressional 21st Century Cures Act. In response, a program of early feasibil
Autor:
David P. Kao, Robert T. Kazmierski, Mona Fiuzat, Bram D. Zuckerman, Marvin A. Konstam, Javed Butler, Peter E. Carson, Meir Shinnar, Christopher M. O'Connor, G. Michael Felker, Ellis F. Unger, JoAnn Lindenfeld, John R. Teerlink, Mitchell A. Psotka, Scott D. Solomon, William T. Abraham, Patrick Verta, Norman Stockbridge, Daniel E. Schaber, Jeffrey Cerkvenik
Publikováno v:
JACC: Heart Failure. 7:913-921
The development of treatments for heart failure (HF) is challenged by burdensome clinical trials. Reducing the need for extensive data collection and increasing opportunities for data compatibility between trials may improve efficiency and reduce res
Autor:
Bram D. Zuckerman, Martin B. Leon, Andrew Farb, Daniel A. Schwartz, Michael J. Mack, Jeff Shuren, Aaron V. Kaplan, Tamara Syrek Jensen, Jamie Waklowiak, Robert 'Chip' Hance, David R. Holmes
Publikováno v:
JACC: Cardiovascular Interventions. 11:2220-2225
Performance of early feasibility studies in the United States can advance the goal of evaluating the safety and effectiveness of new devices aimed at unmet clinical needs and facilitating earlier access for U.S. patients to new technology. Early feas
Autor:
Robert A. Harrington, Daniel A. Canos, Ellis F. Unger, Fady I. Malik, William T. Abraham, Norman Stockbridge, James E. Tcheng, Robert M. Califf, David J. Whellan, Christopher M. O'Connor, Mitchell A. Psotka, Matt Hillebrenner, Michael R. Bristow, Scott D. Solomon, Bram D. Zuckerman, JoAnn Lindenfeld, Mariell Jessup, Mona Fiuzat
Publikováno v:
Journal of the American College of Cardiology. 71:443-453
The current heart failure clinical trial environment is strained by increasing complexity and cost, regulatory requirements, competing demands on stakeholders, implementation challenges, and decreasing patient and investigator participation. To begin
Autor:
Pascal Vranckx, Roxana Mehran, Mitchell W. Krucoff, Stephan Windecker, Andrew Farb, Donald E. Cutlip, Patrick W. Serruys, David P. Taggart, Eugene P. McFadden, Marie-Angèle Morel, Bram D. Zuckerman, John A. Spertus, William F. Fearon, Gregg W. Stone, Gerrit-Anne van Es, Yoshinobu Onuma, Arie-Pieter Kappetein, Hector M. Garcia-Garcia
Publikováno v:
European Heart Journal, 39(23), 2192-2207. Oxford University Press
Autor:
Matthew G. Hillebrenner, Bram D. Zuckerman, Robert M. Califf, Norman Stockbridge, Mona Fiuzat, Shashi Amur, Kristen Miller
Publikováno v:
JACC: Heart Failure. 5:67-70
Autor:
Laura A. Hatfield, Martin B. Leon, Philip G. Jones, Bram D. Zuckerman, Martin Ho, Suzanne V. Arnold, David J. Cohen, John A. Spertus, Jacob V. Spertus
Publikováno v:
Circ Cardiovasc Qual Outcomes
Background: Survival and health status (eg, symptoms and quality of life) are key outcomes in clinical trials of heart failure treatment. However, health status can only be recorded on survivors, potentially biasing treatment effect estimates when th
Autor:
Bram D. Zuckerman, Robert M. Califf, Norman Stockbridge, Susan T. Mayne, Matt Hillebrenner, Mona Fiuzat
Publikováno v:
JACC: Heart Failure. 5:229-231
In recent years, there has been increased recognition of the critical need to improve dietary habits of the general U.S. population as the number of adults with obesity has grown in tandem with the burden of diseases influenced by diet. There is a di
Autor:
Arie-Pieter Kappetein, Gerrit-Anne van Es, Patrick W. Serruys, Mitchell W. Krucoff, William F. Fearon, Marie-Angèle Morel, Pascal Vranckx, Yoshinobu Onuma, Bram D. Zuckerman, David P. Taggart, Eugene P. McFadden, Donald E. Cutlip, Roxana Mehran, John A. Spertus, Stephan Windecker, Hector M. Garcia-Garcia, Gregg W. Stone, Andrew Farb
Publikováno v:
Circulation, 137(24), 2635-2650. Lippincott Williams & Wilkins
Garcia-Garcia, Hector M; McFadden, Eugène P; Farb, Andrew; Mehran, Roxana; Stone, Gregg W; Spertus, John; Onuma, Yoshinobu; Morel, Marie-Angèle; van Es, Gerrit-Anne; Zuckerman, Bram; Fearon, William F; Taggart, David; Kappetein, Arie-Pieter; Krucoff, Mitchell W; Vranckx, Pascal; Windecker, Stephan; Cutlip, Donald; Serruys, Patrick W (2018). Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. European Heart Journal, 39(23), pp. 2192-2207. Oxford University Press 10.1093/eurheartj/ehy223
Garcia-Garcia, Hector M; McFadden, Eugène P; Farb, Andrew; Mehran, Roxana; Stone, Gregg W; Spertus, John; Onuma, Yoshinobu; Morel, Marie-Angèle; van Es, Gerrit-Anne; Zuckerman, Bram; Fearon, William F; Taggart, David; Kappetein, Arie-Pieter; Krucoff, Mitchell W; Vranckx, Pascal; Windecker, Stephan; Cutlip, Donald; Serruys, Patrick W (2018). Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. European Heart Journal, 39(23), pp. 2192-2207. Oxford University Press 10.1093/eurheartj/ehy223
The Academic Research Consortium (ARC)-2 initiative revisited the clinical and angiographic end point definitions in coronary device trials, proposed in 2007, to make them more suitable for use in clinical trials that include increasingly complex les
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d01e30317266810264f936c84cb566c8
https://pure.eur.nl/en/publications/bc1a8a69-8977-4a00-a2a5-e3f17586a726
https://pure.eur.nl/en/publications/bc1a8a69-8977-4a00-a2a5-e3f17586a726
Publikováno v:
Blood pressure monitoring. 22(4)